Clinical trials: Asthma Copd
Asthma
Retrospective Analysis of Systemic Glucocorticoid Mediated Long-term Effects, Patient Pathways and Economic Burden Across Multiple Indications
Glucocorticoids are important in the treatment of many inflammatory, allergic, immunologic, and malignant disorders. However, the adverse effects of systemic corticosteroids are one of the most common causes of iatrogenic…
- Trial name
- NCT06488703
- Where
- Germany
- Volunteers
- 107,032 people
- Sponsor
- GlaxoSmithKline
Asthma
WEUKBRE5554: IMI PROTECT(Work Package 2): Beta2 Agonists and Acute Myocardial Infarction
The studies described in this protocol are all performed within the framework of PROTECT (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium) Work Package 2 and Workgroup 1.
- Trial name
- NCT01636726
- Testing
- Inhaled LABA use
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Asthma
A Study to Evaluate the Effect of Fluticasone/Formoterol Breath Actuated Inhaler (BAI) or Relvar® Ellipta® DPI on Ventilation Heterogeneity in Asthma
The purpose of this study is to demonstrate improvement of peripheral airway resistance (R5-R20) from baseline with fluticasone/formoterol breath actuated inhaler (BAI).
- Trial name
- NCT02753712
- Testing
- Fluticasone/Formoterol BAI, Fluticasone/Vilanterol DPI (Relvar Ellipta DPI)
- Where
- 16 sites in Australia, New Zealand and 3 more
- Volunteers
- 105 people
- Sponsor
- Mundipharma Research Limited
Chronic Obstructive Pulmonary Disease (COPD), Asthma
BREZTRI REGULATORY POST MARKETING SURVEILLANCE IN KOREA
As part of a post-approval commitment requested by the Ministry of Food and Drug Safety (MFDS), this open-label, single-arm, multicentre, observational Post-Marketing Surveillance (PMS) study aims to characterize the safety…
- Trial name
- Breztri rPMS (NCT07570394)
- Where
- 10 sites in South Korea
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Asthma COPD
Clinical and Medico-economic Validation of the HEPHAI Solution.
In a context where the use of inhalation devices for respiratory medications is associated with a high frequency of critical errors, our primary hypothesis is that the use of the HEPHAÏ solution reduces this frequency compared to…
- Trial name
- VAL-HEPHAI (NCT06099145)
- Testing
- Hephaï
- Where
- 5 sites in France
- Volunteers
- 238 people
- Sponsor
- Hephai
Chronic Obstructive Pulmonary Disease, Asthma
Lung Deposition of Beclometasone Dipropionate/Formoterol Fumarate/Glycopyrronium Bromide Administered Via pMDI in Healthy, Asthmatic and COPD Patients
The purpose of this study is to investigate the lung deposition and distribution pattern of Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium Bromide using a Gamma-scintigraphic technique after inhalation of a single…
- Trial name
- NCT02975843
- Testing
- Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
COPD Asthma, Pulmonary Fibrosis
Accuracy of Spircare Device as Compared to the Conventional Plethysmograph
The purpose of this study is to assess the accuracy of FRC and airway resistance calculate values of Spircare device as compared to the conventional body plethysmograph in healthy adults and patients with obstructive and…
- Trial name
- NCT03056066
- Testing
- Plethysmograph
- Where
- Israel
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Spircare Ltd.
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Bioequivalence Study of Synflutide HFA Inhaler and Seretide Evohaler in Healthy Volunteers Without Charcoal Block
The objective of this pivotal study is to evaluate the relative bioavailability of Synflutide HFA 250/25 Inhaler and SeretideTM 250 EvohalerTM in healthy volunteers without charcoal block.
- Trial name
- NCT02466347
- Testing
- Fluticasone propionate, Salmeterol (as xinafoate)
- Where
- Taiwan
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Intech Biopharm Ltd.
Asthma (Part 1), COPD (Part 2)
Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD Subjects
This is a phase I, randomised, placebo-controlled 2-part study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8871 delivered by inhalation, in asthmatic and chronic obstructive pulmonary disease…
- Trial name
- NCT02573155
- Testing
- Dose 1, AZD8871 50 μg (Part 1), Dose 2, AZD8871 100 μg (Part 1), Dose 3, AZD8871 300 μg (Part 1)
- Where
- 2 sites in United Kingdom
- Volunteers
- 134 people
- Sponsor
- AstraZeneca
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV)
The purpose of this study is to evaluate the potential for cardiac repolarization, according to electrocardiographic monitoring (including QT and QTc intervals), of two dose levels of CHF5993 pMDI (beclomethasone…
- Trial name
- NCT05830071
- Testing
- CHF5993, CHF5259, Moxifloxacin 400mg
- Where
- United States
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma, Chronic Obstructive Pulmonary Disease
Study to Assess the Safety and Efficacy of SelK2 on Airway Responses Following Allergen Challenge in Subjects With Asthma (Part 1) and in Subjects With Chronic Obstructive Pulmonary Disease (Part 2)
This study has two parts. The main purpose of Part 1 of this study will be to examine how safe and effective two doses of SelK2 is on participants with mild asthma.
- Trial name
- NCT04540042
- Testing
- SelK2 (Part 1), SelK2 (Part 2)
- Where
- 2 sites in United Kingdom
- Volunteers
- 61 people
- Sponsor
- Tetherex Pharmaceuticals Corporation